(RTTNews) - Ligand Pharmaceuticals Inc. (LGND) Thursday announced a definitive merger agreement with Channel Therapeutics Corp.(CHRO) to combine Ligand's wholly owned subsidiaries, Pelthos ...

Ligand and investors are contributing $50 million to support the Pelthos-Channel merger, set to close summer 2025. FDA-approved Zelsuvmi is the first at-home prescription for molluscum, a skin ...